Our Story

ScitoVation helps clients assess chemical compound safety using innovative science, next-generation technology, and professional expertise. We are known for partnership, flexibility, and proven success in our work to develop safer and more effective pharmaceuticals, food ingredients, agricultural chemicals, commodity chemicals, and consumer products. Being recognized as industry experts in the use of New Approach Methods (NAMs) who have pioneered cell-based and computational methods to provide leading-edge solutions, our results are scientifically sound and withstand scrutiny, including from peer-reviewers and regulators.

At the frontline of next generation risk assessment (NGRA), ScitoVation investigates complex issues, such as chemical modes of action, animal to human exposure extrapolation, and the use of genetic expression and sequencing data to ascertain toxicity. We have innovative people and tools to develop customized cell-based assays to determine safety, model chemical disposition in the body, and analyze and interpret genetic data. Our solutions save our clients time and money by bringing their products to market faster.

Our Team Members

Jean G. Orelien, DrPH, MStat

CEO of ScitoVation

Dr. Orelien is the CEO and President of ScitoVation, LLC a company that helps clients assess the safety of chemical products using in vitro and in silico methods (non-animal approaches). ScitoVation is the recognized leader in the use of innovative science and next-generation technology for assessing chemical safety.  Clients of ScitoVation include the American Chemistry Council, the American Beverage Association and fortune 500 companies.

Prior to ScitoVation, Dr. Orelien served as CEO of SciMetrika, LLC a company he co-founded in 2001. SciMetrika was sold in September 2018 to Inoventures, a federal contractor based in northern Virginia.  During Dr. Orelien’s tenure, SciMetrika achieved more than $100M in billings and performed on more than 150 federal contracts or task order awards. SciMetrika has received numerous awards for growth, including in 2010 the North Carolina Council for Entrepreneurial Development’s Companies to Watch, as well as Inc. magazine’s Top 500 Fastest Growing Companies in both 2010 and 2011. SciMetrika made the list of fastest growing companies in the Triangle four times finishing #2 in 2012.

Dr. Orelien has been honored as one of Inc. magazine’s Top 10 Black Entrepreneurs (2010 and 2011), top 50 African-American in science and technology by Black Money, and in 2011 received the James E. Grizzle Distinguished Alumni Award from the University of North Carolina at Chapel Hill’s (UNC) Department of Biostatistics. He serves as an adjunct professor at the UNC School of Public Health and a board member of the UNC Public Health Foundation (the advisory board for the School of Public Health).

Patrick McMullen, Ph.D.

Director of Computational Toxicology at ScitoVation

Patrick McMullen, Ph.D., is the Director of Computational Toxicology at ScitoVation. Dr. McMullen works with diverse stakeholders spanning government, non-profit, and industry groups to bring new approaches to toxicology, with the goal of improving chemical safety decision-making processes. His research and consulting work combine high-content biological experiments with statistical and computational approaches to advance the understanding of biological fundamentals that underlie chemical safety challenges.

Dr. McMullen’s background in molecular biology, engineering, and computational science has been instrumental in interpreting and communicating complex data problems in diverse applications. Dr. McMullen manages a diverse computational biology team that uses modeling and cell-based experiments to deepen our understanding of how chemicals interact with biological systems. Dr. McMullen earned his Ph.D. in Chemical and Biological Engineering from Northwestern University.

Mel Andersen, Ph.D.

Senior Program Advisor at ScitoVation LLC

Melvin (Mel) Andersen, Ph.D. is Senior Program Advisor at ScitoVation. He has almost 50 years experience in toxicology and risk assessment, primarily developing and applying physiologically based pharmacokinetic and biologically based pharmacodynamic (PBPK) models in quantitative safety assessments. He has worked in the federal government, private industry and academia. In 2007, Dr. Andersen co-authored a National Research Council report, “Toxicity Testing in the 21st Century: A Vision and a Strategy,” and now works with clients to apply new alternative methods (NAMs) and toxicity pathway-based approaches outlined in this report to support chemical safety assessments.

Mel works with clients to assess MOAs using time and dose-related changes in gene expression in cells and tissues, suggests approaches to use NAMs in human health risk assessment and continues his career-long interest in using PK models in safety assessment.  Dr. Andersen has received many awards for professional contributions, including the Frank Blood (1982), Achievement (1984), Arnold J. Lehman (2004) and Merit Awards (2016) from the Society of Toxicology and the Mildred Christian Award for career achievements from the Academy of Toxicological Sciences.

He is a certified industrial hygienist, a diplomate of the American Board of Toxicology and Fellow of the Academy of Toxicological Sciences. He has a Ph.D. in biochemistry and molecular biology from Cornell University.

Marjory Moreau, Ph.D.

Manager of the PMPK division at ScitoVation

Dr. Marjory Moreau is the manager of the PMPK division at ScitoVation. Dr. Moreau’s research focuses on support and advances new human systems biology-based approaches to chemical safety assessment. This work combines research on in vitro biokinetic modeling, physiologically based pharmacokinetic modeling and quantitative in vitro to in vivo extrapolation modeling to translate non-animal and human cell-based toxicity testing results to safe human exposure estimates to support human health assessment.

She completed her Ph.D. in Public Health with a specialty in Toxicology at the University of Montreal, working on the quantitative relationship between exposure to BaP, the temporal evolution of biomarkers of exposure and the appearance of early biological alterations.

She finished her postdoctoral fellowship under the supervision of Andy Nong at Health Canada Computational Toxicology Laboratory. Marjory received support for her research work by the Natural Sciences and Engineering Research Council of Canada (NSERC) which focused on the application of pharmacokinetic models and high throughput screening results to evaluate the potential hazards of chemicals. This work also combined the in-vitro to in-vivo extrapolation approach with biomonitoring studies to bring forth into a public health context.